Table 1.
Demographics and clinical characteristics.
| CLL-FIT (N = 10) |
CLL-UNFIT (N = 10) |
p-Value | 95% CI | Effect Size (d) | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age (years) | 65.8 ± 11.1 | 69.8 ± 10.8 | 0.426 | −14.3, 6.3 | 0.37 |
| Sex (M/F) 1 | 5/5 | 5/5 | 1.000 | 0.00 | |
| Height (cm) | 167.8 ± 17.0 | 170.8 ± 11.9 | 0.648 | −16.8, 10.7 | 0.20 |
| Weight (kg) | 66.2 ± 16.8 | 85.8 ± 24.1 | 0.049 | −39.1, −0.1 | 0.94 |
| BMI (kg/m2) | 23 ± 2.9 | 29 ± 6.2 | 0.013 | −10.5, −1.4 | 1.24 |
| Resting Heart Rate (bpm) | 68 ± 12 | 72 ± 12 | 0.438 | −15.3, 6.9 | 0.33 |
| Clinical Characteristics | |||||
| CLL-IPI Score | 2.4 ± 2.2 | 1.3 ± 1.1 | 0.175 | −0.53, 2.74 | 0.63 |
| RAI Stage [N (%)] 1 | |||||
| Stage 0 | 9 (90) | 7 (70) | 0.453 | ||
| Stage I | 1 (10) | 2 (20) | 0.346 | ||
| Unknown | 0 | 1 (10) | |||
| Disease Duration (years) | 5.0 ± 2.9 | 4.9 ± 2.7 | 0.937 | −2.5, 2.7 | 0.04 |
| Cytogenetics [N (%)] 1 | |||||
| 13q Deletion | 7 (70) | 5 (50) | 0.361 | 0.20 | |
| 17p Deletion | 3 (30) | 0 | 0.060 | 0.42 | |
| 11q Deletion | 2 (20) | 0 | 0.136 | 0.33 | |
| Trisomy 12 | 0 | 2 (20) | 0.136 | 0.33 | |
| TP53 Mutated | 4 (40) | 1 (10) | 0.291 | 0.35 | |
| IGHV Mutated1 | 6 (60) | 6 (60) | 0.766 | 0.16 | |
| CD38 Expression >30% 1 | 1 (10) | 0 | 0.119 | 0.46 | |
| WBC Counts (×103/µL) | 65 ± 54 | 51 ± 51 | 0.553 | −35.1, 63.5 | 0.27 |
| Lymphocytes | 59 ± 52 | 44 ± 49 | 0.517 | −32.7, 62.8 | 0.30 |
| CD19+/CD5+ CLL-cells | 48.1 ± 48.6 | 40.8 ± 41.2 | 0.359 | −35.0, 49.7 | 0.16 |
| CD4+ T-cells | 1.6 ± 2.3 | 5.1 ± 7.4 | 0.169 | −8.6, 1.6 | 0.64 |
| CD8+ T-cells | 0.8 ± 0.9 | 2.2 ± 2.3 | 0.088 | −3.0, 0.2 | 0.80 |
| Monocytes | 1.4 ± 1.4 | 1.8 ± 2.3 | 0.694 | −2.1, 1.5 | 0.21 |
| Neutrophils | 3.4 ± 1.6 | 4.9 ± 1.6 | 0.046 | −3.0, −0.3 | 0.94 |
| Neutrophil: T-cell | 3.7 ± 5.7 | 2.4 ± 2.5 | 0.510 | −2.2, 0.8 | 0.30 |
| T-cell: Monocyte | 2.1 ± 1.4 | 6.5 ± 7.6 | 0.086 | −9.6, 0.7 | 0.81 |
| Platelets (×103/µL) | 149 ± 43 | 196 ± 62 | 0.065 | −96.4, 3.2 | 0.88 |
| Hemoglobin (g/dL) | 13.0 ± 1.7 | 13.6 ± 1.5 | 0.433 | −2.1, 0.92 | 0.37 |
| β2-microglobulin (mg/dL) | 1.9 ± 0.7 | 2.4 ± 0.9 | 0.228 | −1.3, 0.33 | 0.57 |
| ICAM-1 (ng/mL) | 709.1 ± 171.0 | 685.1 ± 158.6 | 0.755 | −136, 184 | 0.15 |
| sCD20 (pg/mL) | 220.8 ± 306.9 | 118.2 ± 181.3 | 0.417 | −158, 364 | 0.40 |
| Fitness and Performance | |||||
| eVO2peak (mL/kg/min) | 34.2 ± 3.3 | 24.9 ± 3.2 | <0.001 | 6.2, 12.4 | 2.86 |
| 6MWT (m) | 500 ± 77 | 399 ± 107 | 0.027 | 12.6, 188 | 1.08 |
| SPPB Score | 12 ± 0 | 9.9 ± 2.4 | 0.012 | 0.52, 3.68 | 1.24 |
| TUG (sec) | 9.4 ± 1.6 | 11.6 ± 4.5 | 0.170 | −5.6, 1.07 | 0.65 |
| Grip Strength Right (kg) | 33.3 ± 12.0 | 32.7 ± 16.7 | 0.930 | −13.1, 14.3 | 0.04 |
| Grip Strength Left (kg) | 32.4 ± 14.3 | 30.5 ± 16.1 | 0.780 | −12.4, 16.3 | 0.12 |
| Best Grip (BMI normalized) | 1.4 ± 0.4 | 1.1 ± 0.5 | 0.171 | −0.15, 0.77 | 0.66 |
| IPAQ (total hours/week) | 31.9 ± 29.1 | 26.4 ± 16.8 | 0.610 | −10.2, 50.6 | 0.23 |
| SBAS [N (%)] 1 | |||||
| Inactive | 2 (20) | 3 (30) | 0.936 | ||
| Light | 4 (40) | 3 (30) | |||
| Moderate | 2 (20) | 2 (20) | 0.21 | ||
| Hard | 1 (10) | 1 (10) | |||
| Very Hard | 1 (10) | 1 (10) | |||
1 Chi-square mean ± SD. BMI (Body Mass Index); CLL-IPI (CLL-International Prognostic Index); IGHV (Immunoglobulin Heavy-Chain Gene); WBC (White Blood Cell); ICAM-1 (Intercellular Adhesion Molecule 1); sCD20 (soluble CD20); 6MWD (6-Minute Walk Test); SPPB (Short Physical Performance Battery); TUG (Timed-Up And Go); IPAQ (Incidental and Planned Activity Questionnaire); SBAS (Stanford Brief Activity Survey). Bolded values represent significant differences between groups. Continuous variables are mean ± SD, and nominal data is N (%).